Biotech Values

[go seek]

a knee-jerk market reaction on the NVS decision not to license...
will not be surprised to see IDIX move back above today's close of @2.50 in short order.

...So we get another company w/ strong anti-viral development experience to opt in. Any guesses on who Idenix may be talking to?

Gilead
Abbott
Glaxo Smith Kline
Schering Plough
Bristol Myers Squibb
Merck
Pfizer
Roche

Some of the above have significant efforts in the HCV space and 'may' fit very well with Idenix / nuc IDX184.

http://www.hcvdrugs.com/
#msg-42917735